S532 P.3.d. Psychotic disorders and treatment − Treatment (clinical) [5] Mitchell, A.J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., De Hert, M. 2013. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders − a systematic review and meta-analysis. Schizophr Bull. 39(2): 306–318. P.3.d.004 Alpha-lipoic acid augmentation improves negative and general psychopathology symptoms in schizophrenia A. Rankovic 1° , V. Djordjevic 2 , B. Djordjevic 3 , B. Vidovic 3 , A. Kuzmanovic 4 , P. Vojvodic 4 , S. Djukic Dejanovic 4 , G. Djokic 4 1 Clinic for psychiatric disorders “Dr Laza Lazarevic”, Department of Biochemistry laboratory, Belgrade, Serbia; 2 Clinic for psychiatric disorders “Dr Laza Lazarevic”, Department of Stomatology, Belgrade, Serbia; 3 University of Belgrade Faculty of Pharmacy, Department of Bromatology, Belgrade, Serbia; 4 Clinic for psychiatric disorders “Dr Laza Lazarevic”, Department of Psychiatry, Belgrade, Serbia Background: Alpha-lipoic acid is a powerful, natural antioxidant with unique benefits in the treatment and prevention of a broad range of diseases [1]. Many evidence indicates on the relationship between oxidative stress and schizophrenia, and the possibility of supplementation with alpha-lipoic acid as the most potent antiox- idant in the adjuvant treatment of patients with schizophrenia [2]. Objective: The aim of this study was to investigate the effect of alpha-lipoic acid supplementation on positive and negative symptoms in patients with schizophrenia. Subjects and Methods: The study included 51 patients treated in Clinic for psychiatric disorders, “Dr Laza Lazarevic” in partial hospital and outpatients program, who were diagnosed with schizophrenia according to ICD 10 criteria (F20.0–F20.9), confirmed by M.I.N.I. 6.0. The patients were randomly divided (biased coin randomization) into two groups: control (n = 24) and study group (n = 27). Patients of both groups were treated with common antipsychotic therapy which was not changed during the study (correction of the antipsychotic therapy was excluding criteria for the study), and study group was treated with additional alpha-lipoic acid, 1000mg per day, under especially prescribed conditions during 8 weeks. The clinical symptoms were evaluated by the Positive and Negative Syndrome Scale (PANSS) with subscales. Patients PANSS score and subscores were evaluated at zero point and after 8 weeks of supplement consumption. The primary data obtained entered in SPSS program (SPSS for Windows, Version 17.00, Chicago: SPSS Inc. 2008) and were analyzed by descriptive statistical methods (measures of central tendency and measures of variability). The methods for testing the difference for numerical data were represented by non-parametric statistical methods, Mann–Whitney and Wilcoxon test. Statistical significance was determined as p < 0.05. Results: Average age was 45.11±9.92 in the study group, and 46.25±7.50 in the control group. Age distribution of subjects indicating the comparability of the studied groups (p = 0.747). Distribution in gender for study group was male 37.5% and female 62.5% and male 33.3% and female 66.6% in the control group. Statistical significance was not found between observed groups, for total PANSS score (p=0.74), positive PANNS sub- score (p = 0.32) and general psychopathology PANSS subscore (p = 0.370). Statistical significance was found between observed groups at zero point for negative PANSS subscore (p = 0.027). Statistical significance was observed in the study group between zero point and after 8 weeks of alpha-lipoic acid augmentation, in terms of the total PANSS score (p=0.013), negative PANSS subscore (p = 0.041) and general psychopathology PANSS sub- score (p = 0.023). There was no statistical significance in the study group between zero point and after 8 weeks of alpha-lipoic acid augmentation according to positive PANSS symptoms (p = 0.104). Conclusion: Our foundings indicates that alpha-lipoic acid aug- mentation as a supplementary, has beneficial effect in treatment of schizophrenic patients. According to our results alpha-lipoic acid augmentation improves negative and general psychopathology PANSS symptoms with statistical significance, and related to that, improves total PANSS symptoms, also with statistical significance. Improving negative PANSS symptoms is even more significant when we take into account that negative PANSS subscore was higher with statistical significance at zero point. References [1] Kim, E., Park, D.W., Choi, S.H., Kim, J.J., Cho, H.S., 2008. A preliminary investigation of a-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia. J Clin Psy- chopharmacol 28(2), 138–146. [2] Vidovi´ c, B., Milovanovi´ c, S., Dord evi´ c, B., Kotur-Stevuljevi´ c, J., Ste- fanovi´ c, A., Ivaniˇ sevi´ c, J., Miljkovi´ c, M., Spasi´ c, S., Stojanovi´ c, D., Pantovi´ c, M., 2014. Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia. Psychiatr Danub 26(3), 205−13. P.3.d.005 The impact of paliperidone palmitate long acting injection on hospital admissions in a mental health setting N. Page 1° , N. Nikolic 1 , A. Akram 2 , M. Khan 2 1 SW London & St Georges Mental Health NHS Trust- Springfield University Hospital, Department of Pharmacy, London, United Kingdom; 2 SW London & St Georges Mental Health NHS Trust- St George’s University of London, Department of Psychiatry, London, United Kingdom Background: Treatment of schizophrenia with depot anti- psychotics is associated with reduced hospital admission rates, as depots can be a cost effective treatment option in a group of patients who may be at risk of non-adherence with oral anti- psychotics [1]. Furthermore, use of depots may decrease the time spent by mental health care professionals on other patient care-related interventions in home treatment teams (HTT). To test this hypothesis, we screened 216 patients in a retrospective observational investigator initiated study who had been prescribed Paliperidone Palmitate Long Acting Injection (PPLAI) for a diagnosis of schizophrenia, schizoaffective disorder and bipolar affective disorder. This study aims to investigate whether PPLAI has an effect on the frequency and length of admissions to mental health inpatient units, the number of contacts with HTT and frequency of home visits by the HTT per patient. Method: We screened male and female patients aged 18 to 65 years, who met the study’s inclusion criteria, patients were iden- tified using the Trust’s stock management and dispensing system. Demographics, drug histories, prior responsiveness to treatment, and care setting at the time of initiation were summarised using the Trust’s Electronic Care Records (ECR) and results reporting database. This study focused on the use of PPLAI over a 6 year period split using a ‘mirror image’ method, beginning from 3 years before PPLAI was approved for use by the Trust’s Drugs and Therapeutics Committee (DTC) to 3 years post-DTC approval. Hospital admission rates, including the inpatient bed days, HTT